On August 10, 2021, the Food and Drug Administration approved the combination of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) for first-line treatment of adult patients with advanced renal cell carcinoma (RCC). Pembrolizumab is an anti-PD-1 checkpoint inhibitor that helps the immune system detect and fight tumor cells. Lenvatinib is an anti-angiogenic targeted therapy that inhibits growth of...
What is No Tie July? No Tie July is our annual fundraising effort where we raise $50,000 – one year of research funding – in just one month! Since our launch in 2016, this fundraising effort has helped us to award $400,000 in direct research grants. How Can You Participate? 1.) Designate a Research Priority This year, we are excited to unveil a new feature of our Research Grant Program...